Should You Buy Axim Biotechnologies Inc (AXIM) Stock on Wednesday?

The market has been high on Axim Biotechnologies Inc (AXIM) stock recently. AXIM gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Axim Biotechnologies Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AXIM!

See Full AXIM Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With AXIM Stock Today?

Axim Biotechnologies Inc (AXIM) stock is unmoved 15.21% while the S&P 500 has gained 0.3% as of 10:48 AM on Wednesday, Sep 13. AXIM is flat $0.00 from the previous closing price of $0.03 on volume of 58,500 shares. Over the past year the S&P 500 has risen 8.88% while AXIM has fallen -57.14%. AXIM lost -$0.05 per share in the over the last 12 months. To screen for more stocks like Axim Biotechnologies Inc click here.

More About Axim Biotechnologies Inc

Axim Biotechnologies Inc is a vertically integrated research and development company focused on improving the landscape for diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, it owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications. Click Here to get the full Stock Report for Axim Biotechnologies Inc stock.